Richard Schwab

Budapest, BU 1125, Hungary

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications

Optimizing Public Health Screening: Population-Specific BMI Thresholds for Targeted Body Composition Assessment in Hungary.

Optimizing Public Health Screening: Population-Specific BMI Thresholds for Targeted Body Composition Assessment in Hungary.

Journal: Nutrients
Published: April 03, 2026

Economic burden of stroke attributable to excess body mass in Hungary: a population-attributable fraction analysis.

Economic burden of stroke attributable to excess body mass in Hungary: a population-attributable fraction analysis.

Journal: BMC public health
Published: November 16, 2025

Real-world performance analysis of a universal computational reasoning model for precision oncology in lung cancer.

Real-world performance analysis of a universal computational reasoning model for precision oncology in lung cancer.

Journal: NPJ precision oncology
Published: November 28, 2024

Lasting Complete Clinical Response of a Recurring Cutaneous Squamous Cell Carcinoma With MEK Mutation and PIK3CA Amplification Achieved by Dual Trametinib and Metformin Therapy.

Lasting Complete Clinical Response of a Recurring Cutaneous Squamous Cell Carcinoma With MEK Mutation and PIK3CA Amplification Achieved by Dual Trametinib and Metformin Therapy.

Journal: JCO precision oncology
Published: January 10, 2022

Personalized First-Line Treatment of Metastatic Pancreatic Neuroendocrine Carcinoma Facilitated by Liquid Biopsy and Computational Decision Support.

Personalized First-Line Treatment of Metastatic Pancreatic Neuroendocrine Carcinoma Facilitated by Liquid Biopsy and Computational Decision Support.

Journal: Diagnostics (Basel, Switzerland)
Published: September 07, 2021

A computational method for prioritizing targeted therapies in precision oncology: performance analysis in the SHIVA01 trial.

A computational method for prioritizing targeted therapies in precision oncology: performance analysis in the SHIVA01 trial.

Journal: NPJ precision oncology
Published: September 24, 2020

Major Clinical Response to Afatinib Monotherapy in Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion Mutation.

Major Clinical Response to Afatinib Monotherapy in Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion Mutation.

Journal: Clinical lung cancer
Published: June 16, 2020

Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers.

Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers.

Journal: PloS one
Published: May 08, 2017

MDR-1 and MRP-1 activity in peripheral blood leukocytes of rheumatoid arthritis patients.

MDR-1 and MRP-1 activity in peripheral blood leukocytes of rheumatoid arthritis patients.

Journal: Diagnostic pathology
Published: September 28, 2015

Decreased functional activity of multidrug resistance protein in primary colorectal cancer.

Decreased functional activity of multidrug resistance protein in primary colorectal cancer.

Journal: Diagnostic pathology
Published: October 13, 2014

Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement.

Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement.

Journal: Lung cancer (Amsterdam, Netherlands)
Published: July 02, 2013
Showing 1-11 of 11

Last Updated: 09/26/2026